Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GLB1 | P16278 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12838397 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10072844 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12858933 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL20131364 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL17110046 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24686930 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL10051725 | 0.87 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL24686932 | 0.87 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL25964778 | 0.86 | ALDH1A1 (0.34) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL7151496 | 0.83 | PI4KA (0.33) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016135582-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-9173892-B2 | Acadesine derivatives, products and compositions including same, therapeutic uses thereof, and methods for synthesizing same | UNIVERSITE NICE SOPHIA ANTIPOLIS (FR) | 2015-11-03 | — | — | US | disclosed |
| EP-2699240-B1 | ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPEUTIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME | UNIVERSITÉ NICE SOPHIA ANTIPOLIS (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | PI4KA 1316/4885PI4K2B 1913/4885PI4K2A 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.